Evidence map›Paper›PMID 26848154›Full record

ArticleThe EMBO journal2016

Mitochondria are required for pro-ageing features of the senescent phenotype.

Clara Correia-Melo, Francisco D M Marques, Rhys Anderson, Graeme Hewitt, Rachael Hewitt, John Cole, Bernadette M Carroll, Satomi Miwa, Jodie Birch, Alina Merz and 18 more

Open access · hybridAbstract read
In one paragraph

Article in The EMBO journal, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 466 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
466citing papers in PubMed, 3 pooled it
38.0field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

466 citing papers in PubMed, 3 syntheses or guidelines pooled it, 754 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Review
  18. Review
  19. Review
  20. Review

406 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

28 authors at 7 institutions in 4 countries.

Clara Correia-MeloInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK GABBA Program, Abel Salazar Biomedical Sciences Institute University of Porto, Porto, Portugal.
Francisco D M MarquesInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Rhys AndersonInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Graeme HewittInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Rachael HewittInstitute of Cancer Sciences, CR-UK Beatson Institute, University of Glasgow, Glasgow, UK.
John ColeInstitute of Cancer Sciences, CR-UK Beatson Institute, University of Glasgow, Glasgow, UK.
Bernadette M CarrollInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Satomi MiwaInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Jodie BirchInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Alina MerzInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Michael D RushtonInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Michelle CharlesInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Diana JurkInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Stephen W G TaitInstitute of Cancer Sciences, CR-UK Beatson Institute, University of Glasgow, Glasgow, UK.
Rafal CzapiewskiInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Laura GreavesWellcome Trust Centre for Mitochondrial Research, Newcastle University Centre for Brain Ageing and Vitality, Newcastle University, Newcastle upon Tyne, UK.
Glyn NelsonInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Mohammad Bohlooly-YTransgenic RAD, Discovery Sciences, AstraZeneca, Mölndal, Sweden.
Sergio Rodriguez-CuencaMetabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Antonio Vidal-PuigMetabolic Research Laboratories, Wellcome Trust-MRC Institute of Metabolic Science, Addenbrooke's Hospital, University of Cambridge, Cambridge, UK.
Derek MannFaculty of Medical Sciences, Institute of Cellular Medicine, Newcastle University, Newcastle upon Tyne, UK.
Gabriele SaretzkiInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Giovanni QuaratoDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Douglas R GreenDepartment of Immunology, St. Jude Children's Research Hospital, Memphis, TN, USA.
Peter D AdamsInstitute of Cancer Sciences, CR-UK Beatson Institute, University of Glasgow, Glasgow, UK.
Thomas von ZglinickiInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
Viktor I KorolchukInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK.
João F PassosInstitute for Cell and Molecular Biosciences, Campus for Ageing and Vitality, Newcastle University Institute for Ageing, Newcastle University, Newcastle upon Tyne, UK joao.passos@ncl.ac.uk.
Newcastle University · GBNewcastle Hospitals - Campus for Ageing and Vitality · GBAddenbrooke's Hospital · GBCancer Research UK Scotland Institute · GBSt. Jude Children's Research Hospital · USUniversity of Glasgow · GBAstraZeneca (Sweden) · SE

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI CHARLES ROBERTS · 1985 to 2026
$166.9M
Survival Function of the Fadd-Caspase-8-Flip ComplexR01AI044828 · NIAID · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI GREEN, DOUGLAS R. · 1999 to 2016
$6.3M
TARGETING OF LIPOSOMES TO TUMOR CELLSK04CA000718 · NCI · UNIVERSITY OF TENNESSEE KNOXVILLE · PI HUANG, LEAF · 1985 to 1985
–
Biotechnology and Biological Sciences Research Council BB/F010966/1Biotechnology and Biological Sciences Research Council BB/H022384/1Biotechnology and Biological Sciences Research Council BB/I020748/1Biotechnology and Biological Sciences Research Council BB/K017314/1Biotechnology and Biological Sciences Research Council BB/K019260/1Medical Research Council G0400192Medical Research Council G0700718Medical Research Council MC_G0802535Medical Research Council MC_UU_12012/2Medical Research Council MR/K001949/1Medical Research Council MR/K006312/1Medical Research Council MR/L016354/1NCI NIH HHS P30 CA021765NIAID NIH HHS R01 AI044828
6 · The paper itself

Abstract

Cell senescence is an important tumour suppressor mechanism and driver of ageing. Both functions are dependent on the development of the senescent phenotype, which involves an overproduction of pro-inflammatory and pro-oxidant signals. However, the exact mechanisms regulating these phenotypes remain poorly understood. Here, we show the critical role of mitochondria in cellular senescence. In multiple models of senescence, absence of mitochondria reduced a spectrum of senescence effectors and phenotypes while preserving ATP production via enhanced glycolysis. Global transcriptomic analysis by RNA sequencing revealed that a vast number of senescent-associated changes are dependent on mitochondria, particularly the pro-inflammatory phenotype. Mechanistically, we show that the ATM, Akt and mTORC1 phosphorylation cascade integrates signals from the DNA damage response (DDR) towards PGC-1β-dependent mitochondrial biogenesis, contributing to aROS-mediated activation of the DDR and cell cycle arrest. Finally, we demonstrate that the reduction in mitochondrial content in vivo, by either mTORC1 inhibition or PGC-1β deletion, prevents senescence in the ageing mouse liver. Our results suggest that mitochondria are a candidate target for interventions to reduce the deleterious impact of senescence in ageing tissues.

Indexed as

AgingAnimalsCell LineHumansMiceMitochondriaModels, BiologicalPhenotypeageinginflammationmitochondriamTORsenescence

Identifiers

PMID26848154
PMCPMC4818766
OpenAlexW2267737556

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.